Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Benign prostatic hyperplasia is a noncancerous (benign) enlargement of the endocrine that may build micturition troublesome. Benign prostatic hyperplasia (BPH) becomes more common as men age, particularly after age 50. The precise cause isn't known however most likely involves changes caused by hormones, including testosterone and especially dihydrotestosterone. BPH, which affects 110 million men worldwide, is an enlargement of the prostate in which prostate adenoma cells form excess tissue that may cause symptoms, which impact a patient's quality of life, such as a frequent and urgent need to urinate.
Growing geriatric populace, increasing demand for minimally invasive therapies coupled with the continuous technologic advancements have led to the development of BPH devices with superior quality and safety. Moreover, technological advancements have supported the development of minimally invasive BPH procedures with increased safety and efficacy.
As men age, the prostate can become enlarged, restricting or blocking urine flow. As indicated by the National Institute on Aging the world’s geriatric population in 2015 was around 8.5% and it is anticipated to rise around 17% by 2050. This statistics highlight the need of growing demand home infusion therapy, this population possesses a high risk and. More than half of all men in their 60s and as many as 90% of men in their 70s and 80s have some symptoms of benign prostatic hyperplasia. Hence, staggering growth in patient pool likely to offer numerous growth opportunities for product manufacturers.
The report analyses the benign prostatic hyperplasia devices market based on procedure type, end user, and geography.
The Benign Prostatic Hyperplasia is treated by various procedures including transurethral resection of the prostate (TURP), transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA), laser surgery, prostatic stenting, etc. Transurethral resection of the prostate (TURP) is a surgery used to treat urinary problems due to an enlarged prostate. Transurethral resection of the prostate (TURP) is a surgical procedure to remove excess part of the prostate gland which obstructs normal urine flow. Visual, hands-on access to the prostate, immediate removal of excess tissue and ability to combine with other procedures are some of the advantages of TURP over other available treatment options for lower urinary tract infections.
The major end user of the market are hospital & clinics and ambulatory surgical canters. Hospitals segment held the significant market benign prostatic hyperplasia devices owing to the increase in the number of surgeries being performed at hospitals coupled with the availability of advanced healthcare facilities and increasing affordability of treatment due to the rising disposable income. Further, the demand of prostatic hyperplasia devices in ambulatory surgical centre is growing due to various benefits offered by ambulatory centers such as short stay, cost-effectiveness, reduced risk of hospital acquired infections.
By geography, the global benign prostatic hyperplasia devices market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world regions which includes Latin America, and Middle East & Africa.
North America accounted for the largest share of the Benign Prostatic Hyperplasia Devices Market in 2018. The large share in the North American region is mainly attributed to the high prevalence rate of benign prostatic hyperplasia, rising geriatric population is bolstering the growth of the market. However, Asia is the fastest growing market due to the rise in various urological disorders and complications, improving healthcare infrastructure, growing geriatric population and increasing number of public awareness programs in the region.
The major players in the global benign prostatic hyperplasia devices include Endo International plc, KARL STORZ GMBH & CO.KG, Lumenis, Olympus corporation, Urologix, Inc., Boston Scientific corporation, Coloplast A/S, Lisa Laser, Medifocus, Inc., Neotract, Inc., ProArc Medical LTD., and Urotech GMBH among others.
The report analyses the benign prostatic hyperplasia devices market based on procedure type, end user, and geography. The Benign Prostatic Hyperplasia is treated by various procedures including transurethral resection of the prostate (TURP), transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA), laser surgery, prostatic stenting, etc. The major end user of the market are hospital & clinics and ambulatory surgical canters. By geography, the global benign prostatic hyperplasia devices market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world regions which includes Latin America, and Middle East & Africa.
The major players in the global benign prostatic hyperplasia devices include Endo International plc, KARL STORZ GMBH & CO.KG, Lumenis, Olympus Corporation, Urologix, Inc., Boston Scientific Corporation, Coloplast A/S, Lisa Laser, Medifocus, Inc., Neotract, Inc., ProArc Medical LTD., and Urotech GMBH among others.
Why to Buy This Report:
